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Abstract
The surgeon general of the USA defines osteoporosis as “a skeletal disorder characterized by compromised bone strength,
predisposing to an increased risk of fracture.” Measuring bone strength, Biomechanical Computed Tomography
analysis (BCT), namely, finite element analysis of a patient’s clinical-resolution computed tomography (CT) scan, is now
available in the USA as a Medicare screening benefit for osteoporosis diagnostic testing. Helping to address under-diagnosis
of osteoporosis, BCT can be applied “opportunistically” to most existing CT scans that include the spine or hip regions and were
previously obtained for an unrelated medical indication. For the BCT test, no modifications are required to standard clinical CT
imaging protocols. The analysis provides measurements of bone strength as well as a dual-energy X-ray absorptiometry (DXA)–
equivalent bone mineral density (BMD) T-score at the hip and a volumetric BMD of trabecular bone at the spine. Based on both
the bone strength and BMD measurements, a physician can identify osteoporosis and assess fracture risk (high, increased, not
increased), without needing confirmation by DXA. To help introduce BCT to clinicians and health care professionals, we
describe in this review the currently available clinical implementation of the test (VirtuOst), its application for managing patients,
and the underlying supporting evidence; we also discuss its main limitations and how its results can be interpreted clinically.
Together, this body of evidence supports BCT as an accurate and convenient diagnostic test for osteoporosis in both sexes,
particularly when used opportunistically for patients already with CT.
Mini Abstract
Biomechanical Computed Tomography analysis (BCT) uses a patient’s CTscan to measure both bone strength and bone mineral
density at the hip or spine. Performing at least as well as DXA for both diagnosing osteoporosis and assessing fracture risk, BCT
is particularly well-suited to “opportunistic” use for the patient without a recent DXA who is undergoing or has previously
undergone CT testing (including hip or spine regions) for an unrelated medical condition.
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Introduction
The surgeon general of the USA defines osteoporosis as “a
skeletal disorder characterized by compromised bone
strength, predisposing to an increased risk of fracture” [1, 2]
and the International Osteoporosis Foundation defines oste-
oporosis as “a condition where bones become thin and lose
their strength” [3]. Since it has not yet been possible clinically
to measure a patient’s bone strength non-invasively, osteopo-
rosis is usually diagnosed by measuring bone mineral density
(BMD) using dual-energy X-ray absorptiometry (DXA). This
approach is limited in two ways. First, rates of diagnostic
testing by DXA are low. In particular, each year, only 9.5%
of eligible Medicare women and 1.7% of men in the USA get
diagnostically screened for osteoporosis by DXA [4]. That
low screening rate is of concern because it hinders osteoporo-
sis care [5–8] and is thought to contribute to the now rising
incidence rate of hip fracture in the USA [9]. This under-
diagnosis problem is widely recognized [4–8, 10–12] and is
urgent because the size of the elderly population is continuing
to increase [13].
A second limitation with current osteoporosis assessment is
that the BMDmeasurement from DXA does not directly mea-
sure bone strength, the subject of osteoporosis. While bone
strength does indeed correlate with BMD [14], a DXA-
derived BMD measurement does not mechanistically capture
potentially important elements of bone strength such as the
bone’s overall shape and three-dimensional geometry, the rel-
ative amount of cortical and trabecular bone, local variations
in cortical thickness, and the internal spatial distribution of
bone density. This limitation partly explains why DXA has
limited sensitivity [15–20] for correctly predicting who will
fracture.
Given these limitations, it is significant that a well-validat-
ed, convenient diagnostic test for osteoporosis that non-
invasively assesses bone strength is now available clinically
in the USA as a reimbursed Medicare screening benefit for
osteoporosis. Formally referred to by the American Medical
Association as “Biomechanical Computed Tomography”
analysis (BCT), the test comprises a finite element analysis
of bone strength using as input a clinical resolution CT scan
[21]; it also includes CT-based measurements of BMD and
DXA-equivalent hip BMD T-scores. First reported in 1991
[22] and used since by multiple groups in research
settings—extensive reviews are provided elsewhere
[23–26]—the finite element analysis component of BCT rep-
resents a “virtual stress test” that provides a functional non-
invasive assessment of the breaking strength of the patient’s
hip (proximal femur) or spine (vertebral body). Currently, the
only clinically available, FDA-cleared implementation of
BCT in the USA is by the VirtuOst® software (O.N.
Diagnostics, Berkeley, CA), a regulated class-II medical de-
vice that is the focus of this report.
Importantly for patient convenience, the VirtuOst imple-
mentation of BCT can utilize most hip- or spine-containing
CTscans taken previously for any medical indication, without
requiring any change to how those CT scans are originally
acquired. Used in this way—so-called opportunistic use—
the patient does not need to undergo any extra imaging for
the BCT test and there is zero radiation exposure associated
with the BCT test per se. Millions of patients in the osteopo-
rosis demographic are scanned with CT covering the hip or
spine each year. For example, in the US Medicare population
in 2018, 6.8 million reimbursed CT exams of the abdomen or
pelvis were performed and 2.6 million DXA exams [27].
Assuming that 40% of those DXA exams were taken for di-
agnostic screening purposes [4], these data imply that over
sixfold more hip-containing CT exams were performed in
2018 than diagnostic DXA exams. Thus, opportunistic BCT
could have appreciable clinical impact if widely used for di-
agnostic screening purposes in the older CT patient popula-
tion. This review focuses primarily on this opportunistic use of
BCT.
To help introduce the BCT test to clinicians and health care
professionals, we review here the VirtuOst BCT test, describe
how it can be used to manage patients, and suggest how its
results are best interpreted in a clinical setting. We also review
the available supporting evidence, with additional detail pro-
vided in a series of appendices (see SupplementaryMaterials).
Lastly, we also discuss some key clinical issues that arise
when using BCT to manage patients for osteoporosis, includ-
ing the test’s main limitations. Unlike other technical reviews
of the finite element analysis component of BCT [23–26],
unless noted otherwise, all data reviewed here relate to the
VirtuOst implementation of BCT or its earlier versions, with
a focus on its use in a clinical setting.
BCT as a clinical test
What is the BCT test?
Utilizing the information in the patient’s CT scan as input,
BCT performs a virtual stress test to compute a measure-
ment of bone strength, which is the force (in units of
newtons) required to virtually break or fracture the pa-
tient’s hip or spine in a standardized loading configura-
tion. The virtual stress test combines advanced medical
image processing, principles of bone biomechanics, and
the well-established engineering structural analysis tech-
nique of non-linear finite element analysis to simulate
what is thought to characterize a typical fracturing event:
a sideways fall for hip fracture and a compressive over-
load for vertebral fracture (Fig. 1). The VirtuOst BCT test
also provides measurements of BMD that are statistically
equivalent to those provided by either DXA at the hip or
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quantitative CT at the spine (Fig. 1). Overall, the follow-
ing measurements are provided at the hip or spine or both,
depending on the type of CT scan used as input:
& Hip measurements: proximal femoral strength for a stan-
dardized sideways fall; DXA-equivalent BMD T- and Z-
scores for the femoral neck and total hip regions (can use
the NHANES or other reference populations); plots of
proximal femoral strength and femoral neck BMD T-
score versus age with reference population means and
standard deviations. Since the BMD T-score from BCT
is statistically equivalent to that from DXA, it can be used
with FRAX® [28] or other risk calculators.
& Spine measurements: vertebral strength for a compressive
overload; vertebral trabecular volumetric BMD, with Z-
scores; plots of vertebral strength and BMD versus age
with reference population means and standard deviations.
Note, as per clinical guidelines, T-scores are not used with
vertebral trabecular BMD [29, 30]. As discussed below,
the BCT volumetric BMD spinal measurement may have
some advantages over a DXA spine BMD measurement
because the volumetric measurement is minimally influ-
enced by typical degenerative changes in the posterior
elements, on the vertebral surfaces, or in the adjacent vas-
culature, any of which can compromise the accuracy of
the DXA measurement.
& Classification of fracture risk: based on these hip and spine
measurements and using clinically validated cut-points,
various classifications are provided to arrive at an overall
fracture risk classification for the patient (high, increased,
or not increased).
Details of the (VirtuOst) BCT test
Described in detail elsewhere [31, 32], starting with a hip- or
spine-containing routine clinical CT scan, the target bone in
Fig. 1 The BCT measurements for the hip (top) and spine (bottom). The
finite element models (sectioned to show internal detail) depicting: (left)
the spatial distribution of BMD (in grayscale) before virtual loading, and
(center) the deformed shape and failed tissue (in colors) after virtual
loading; deformed shape is amplified for clarity. Right: the regions of
interest (in yellow) for the BMD measurements
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the patient’s CT scan is first identified—a proximal femur
(nominally the left femur) or a single vertebral body (prefera-
bly L1, or any one level within T12 to L3). The bone is then
isolated from the surrounding tissues and organs (posterior
elements are virtually removed for the spine) using advanced
image processing. Unlike with spinal DXA for which four
vertebral levels are typically assessed, analysis of just one
[33, 34] or two [35] vertebral levels (between T12 and L3)
by BCT has been shown to be effective for spinal fracture
prediction; similarly, analysis of just one femur is adequate
for hip fracture prediction [16, 20, 35]. To provide a patient-
specific calibration and therefore enable a diagnostic-quality
measurement of BMD, the CT scan is calibrated using either
an external calibration phantom (typical in research studies) or
a phantomless approach (typical in clinical practice) using
internal tissues as references (details below). Next, the isolated
bone is registered into a standardized coordinate system either
by mapping the patient’s proximal femur onto a reference
femur that is already in a standardized orientation for virtual
loading or by ensuring the vertebral endplates are horizontally
oriented. For monitoring changes over time, at each time
point, the isolated bones can be virtually registered to each
other to optimize precision for measuring temporal changes.
The isolated, calibrated, and registered bone is then converted
into a finite element model comprised of 1.0-mm-sized cube-
shaped, eight-node brick elements. Models for the proximal
femur, for example, typically have 100,000–200,000 finite
elements.
For each finite element in the model, element-specific bio-
mechanical elastic and strength material properties are gener-
ated directly from the calibrated CT scan data, based on em-
pirical relations obtained from biomechanical testing of hu-
man cadaveric bone specimens [36–39]. When interpreting
results from a BCT test, it is noteworthy that those relations
reflect the biomechanical behavior of typical human bone.
These relations therefore do not capture any molecular level
defects that might occur in some individuals, for example,
patients with collagen or mineral deficiencies that can appre-
ciably alter the mechanical properties independent of the
BMD. As a result, for these patients, the assumed relation in
the BCT model between mechanical properties and BMD at
the tissue level could differ from the true relation, which could
introduce an error in their BCT strength measurement.
After constructing the finite element model, loading condi-
tions are applied. The VirtuOst implementation of BCT simu-
lates a uniform compressive over-loading of the spine or a
sideways fall of the hip, both applied via a thin layer of plastic
over the bone surface to mimic laboratory biomechanical test-
ing conditions (Fig. 1). Finally, a computationally non-linear
finite element analysis is performed, solving hundreds of
thousands of simultaneous equations multiple times per sim-
ulation, and the resulting non-linear force-deformation curve
is processed to provide the output measurement of the whole-
bone breaking strength. Ongoing research is addressing the
potential clinical utility of accounting for different types of
loading configurations in this process, including applying
multiple different forces and simulating dynamic impact
[40–42]. Thus, as the BCT technology continues to evolve,
if proven beneficial, some aspects of the virtual stress testing
may change.
When BCT is used opportunistically (e.g., using CT scans
not acquired specifically for bone assessment), unique techni-
cal challenges arise related to ensuring the following: (1) ad-
equate quality of the image and proper quantitative calibration
of the scan and (2) consistency of BCT results across patients,
especially when different CT scanners and acquisition settings
are used, as is typical for opportunistic use. For example, too
much image noise, including metal artifacts, can compromise
the calibration and overall analysis; sharp kernels (e.g., the
“bone” kernel) or unusual reconstruction filters can distort
the underlying grayscale data [43]; and low voltage settings
(≤ 80 kVp) can lead to excessive noise. All these factors
would disqualify an analysis if the artifacts are manifested in
the calibration reference tissues or the bone of interest; typi-
cally, for example, scans are not analyzed if there is any metal
in the transverse plane of the bone of interest, e.g., a hip pros-
thesis in either proximal femur or a posterior fixation rod that
spans T12 to L3. That said, most current clinical CT scans do
not exhibit these characteristics and therefore 85–95% of
scans can be processed. Intravenous contrast is not a problem
for BCT at the hip but can compromise a spine analysis [44],
and therefore, BCT is not typically recommended for a spinal
scan acquired with intravenous contrast [45]. Excessive de-
generative changes do not invalidate an analysis but can re-
quire additional image processing and more nuanced clinical
interpretation. Hip scans that do not extend sufficiently toward
the lesser trochanter cannot be used for a bone strength anal-
ysis, although the femoral neck BMD can be measured from
slightly shorter scans.
Since BCT as a clinical test is new, widespread standards
and practice guidelines do not yet exist. One immediate chal-
lenge is to ensure that the highly technical BCT analysis is
properly executed and that results remain consistent across
software updates, over time, and when obtained by different
technicians and on different CT scanners. The FDA-regulated
nature of the VirtuOst software and the associated software
engineering controls ensure that results remain consistent
across software updates and over time; the software algo-
rithms also account for different CT scanner characteristics
via manufacturer- and acquisition-specific adjustments in the
calibration process. In addition, the VirtuOst test is currently
only available via a centralized laboratory service (O.N.
Diagnostics, Berkeley, CA). For that service, scans are sent
to the laboratory for BCT analysis, where uniquely trained
technicians perform the analysis under strict controls. This
overall approach helps ensure that all VirtuOst-based BCT
Osteoporos Int (2020) 31:1025–10481028
analyses are performed in an expert and consistent manner
across different technicians, CT scanners, acquisition settings,
patients, and over time.
Clinical interpretation of BCT results
By comparing a patient’s measurements of bone strength and
BMD to respective interventional thresholds (see below),
BCT provides classifications for fragile bone strength, low
bone strength, and normal bone strength and for (BMD-
defined) osteoporosis, low bone mass (aka, osteopenia), and
normal bone mass (Table 1). Based on those classifications,
an overall fracture risk classification is assigned following
traditional DXA criteria [46], expanded to consider also the
bone strength measurements:
& High risk, if the patient tests positive either for fragile
bone strength or (BMD-defined) osteoporosis, or both,
at either the hip or spine
& Increased risk, if the patient is not at high risk and instead
tests positive for either low bone strength or low bone
mass, or both, at either the hip or spine
& Not increased risk, if both bone strength and BMD are in
the normal range at all measured sites
As cleared by the FDA, these classifications can be used by
a physician to diagnose osteoporosis and assess fracture risk.
For example, the International Society for Clinical
Densitometry’s practice guidelines for initiating therapeutic
treatment [23] recommend that patients be considered for ther-
apeutic treatment if classified as having fragile bone strength.
As discussed in more detail below, results from BCT do not
need to be confirmed by DXA, although some physicians may
decide to subsequently order a baseline DXA for use in mon-
itoring a treatment response.
Using these criteria, a slightly greater number of patients
will test positive, and presumably more will be treated, than if
one were to define high-risk patients on the basis of fragile
bone strength alone or BMD alone.When using only hip BCT,
the prevalence of high-risk patients by BCT appears to be
similar to the prevalence of BMD-defined osteoporosis based
on traditional DXA criteria (BMDT-score ≤ − 2.5 at the hip or
spine). For example, in the large real-world FOCUS study of
hip fractures [20] (the “Fracture, Osteoporosis, and CT
Utilization Study”, see below for details), prevalence of
high-risk women by hip BCT using the above criteria was
30%, which was similar to the prevalence of 28% by tradi-
tional (hip/spine) DXA criteria (for patients not treated previ-
ously with osteoporosis medications). Based on these data, the
number of positive testing patients should be similar if hip
BCT is used instead of traditional DXA. As discussed below
in more detail, the FOCUS study also demonstrated that these
high-risk women (by hip BCT) were at significantly higher
risk of hip fracture than those identified by traditional (hip/
spine) DXA.
If BCT is performed at both the hip and spine, more high-
risk patients by the above criteria will be expected than if
using only hip BCT. One small study on CT colonography
patients (age 43–92 years) reported the prevalence of high-
risk patients when using both hip and spine BCTas compared
to prevalence of BMD-defined osteoporosis by traditional
DXA (hip/spine) [47]. That study reported prevalence of
33% by hip/spine BCT versus 27% for hip/spine DXA for
106 women, suggesting that use of hip/spine BCT will in-
crease the number of positive-testing patients versus tradition-
al (hip/spine) DXA. Additional and larger studies are required
to characterize the risk profile of those patients. However,
Table 1 Interventional thresholds for bone strength [35] (in newtons,
N) and BMD (in dimensionless DXA-equivalent T-score units for the hip
or mg/cm3 for the spine). A patient is considered at high risk of fracture if
any measurement falls within the italicized entries. The bone strength
thresholds were developed based on a statistical correspondence between
BMD and bone strength, measured in hundreds of patients in cohorts
independent of those used for their prospective validation. The BMD
thresholds are based on established guidelines. See Appendix C for fur-
ther details and the related validation studies
Classification Women Men
Hip Spine Hip Spine
Fragile bone strength ≤ 3000 N ≤ 4500 N ≤ 3500 N ≤ 6500 N
Low bone strength > 3000 to < 4000 > 4500 to < 6000 > 3500 to < 5000 > 6500 to < 8500
Normal bone strength ≥ 4000 ≥ 6000 ≥ 5000 ≥ 8500
Osteoporosis ≤ − 2.5 ≤ 80 mg/cm3 ≤ − 2.5 ≤ 80 mg/cm3
Low bone mass (osteopenia) > − 2.5 to < − 1.0 > 80 to < 120 > − 2.5 to < − 1.0 > 80 to < 120
Normal bone mass ≥ − 1.0 ≥ 120 ≥ − 1.0 ≥ 120
The strength thresholds were developed and validated for measurement by VirtuOst. Strength is reported to ± 10 N, BMD T-score to ± 0.1 unit, and
volumetric BMD to ± 1 mg/cm3 . For the overall fracture risk classification (see text), a patient is classified as being at: high risk if testing test positive for
fragile bone strength or (BMD-defined) osteoporosis or both, at either the hip or spine; not increased risk if both bone strength and BMD are in the
normal range at all measured sites; or increased risk otherwise
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since about 60–70% of abdominal scans (at least in the USA)
are performed with intravenous contrast, which precludes ac-
curate analysis of the spine [44], the issue of performing both
hip and spine BCT will not arise for most patients in typical
clinical practice. That said, sagittal reconstructions from ab-
dominal scans with intravenous contrast can be used to iden-
tify prevalent vertebral fractures in the lumbar region [48, 49].
The clinical utility of combining such measurements with hip
or spine BCT or both remains to be investigated.
Occasionally, some patients classified by BCT as high risk
will have fragile bone strength without having BMD-defined
osteoporosis. Mechanistically, such patients might have small
bones, a relatively porous trabecular but normal cortical com-
partment [50], unusual 3D geometry, unusual spatial distribu-
tion of bone density, focally thin cortices [51], or weak subre-
gions. These features are typically not reflected by the DXA
BMD T-score but can be captured in the less averaged and
more mechanistic finite element analysis, explaining why
BCT-based bone strength has been found to predict incident
fractures independently of BMD at both the spine [33, 35] and
hip [20, 35]. Supported by the clinical evidence discussed
below, these patients with fragile bone strength are classified
as being at high risk of fracture regardless of the BMD mea-
surement. Less commonly, some patients may be classified to
have BMD-defined osteoporosis without fragile bone
strength. As per traditional but well-established clinical guide-
lines, because these patients have BMD-defined osteoporosis,
they are also classified as being at high risk of fracture regard-
less of the bone strength measurement. Patients testing posi-
tive for both fragile bone strength and BMD-defined osteopo-
rosis are at additionally increased risk [20].
Typical uses of BCT
To date, measurement of BMD byDXA has been the standard
of care for osteoporosis testing for all patients. Going forward,
based on the evidence reviewed below, BCT could now be
considered as an accurate alternative to DXA for the following
two situations:
For opportunistic use
BCTwould be appropriate for a patient who has had a recent
CTor is about to undergo a CT for any medical indication and
who satisfies both of the following criteria:
& would benefit medically from an accurate osteoporosis
test and who meets clinical guidelines for osteoporosis
testing
& has had a hip- or spine-containing CT scan for any indi-
cation (for hip: any abdominal or pelvic CT, including
whole-body CT; for spine: any CT without intra-venous
contrast containing one or more lumbar or lower thoracic
vertebrae)
For this situation, the patient does not need to undergo any
extra imaging procedure for diagnostic purposes and there is
no extra radiation exposure because the patient’s CT scan has
already been acquired or ordered for other reasons. The
FOCUS study [20] from Kaiser Permanente Southern
California established the robustness of this opportunistic ap-
proach for BCT, sampling all available hip-containing CT
scans from a cohort of 111,694 patients, acquired on 80 dif-
ferent CT scanners, across 14 hospitals, over a 9-year time
frame. Approximately two-thirds of the CT scans were ac-
quired using intravenous contrast, and more than one-third
of CT scans had a slice thickness between 3 and 5 mm. In
total, 86% of all available hip-containing CT scans were ana-
lyzable by BCT, the most common reason for rejection being
insufficient distal bone coverage by the scan (more common
in abdominal than in pelvic or pelvic-abdominal scans).
For non-opportunistic use
BCT with a dedicated CT scan would be appropriate for pa-
tients for whom a DXA test is either not easily available,
inadequate, or inconclusive. Examples include institutions or
regions with CT but without DXA facilities; if appreciable
bone deformities or degenerative changes exist that would
compromise the accuracy of a DXA measurement; if the pa-
tient is highly obese, which can be particularly problematic for
DXA [52, 53]; or if more detail is required for assessment
purposes than is provided by DXA. An example of the latter
would be a patient presenting with a wrist fracture who has
low bone mass by DXA and for whom additional information
on the hip or spine is required to make a diagnosis.
For opportunistic BCT, the patients’ primary care physician
or health care provider would typically order the BCT test at
some time after the original CTwas taken; the physician who
ordered the original CT would typically not be involved. In
addition, depending on the particular hospital system and re-
gional practice guidelines, there are applications for which the
same physician who orders the original CT scan may simulta-
neously order BCT. Examples include (Table 2) patients un-
dergoing the following: CT enterography for assessment of
inflammatory bowel disease (IBD) [45], CT colonography
for colorectal cancer screening [47], spine CT before spinal
fusion surgery [55], or PET/CT for staging prostate cancer
[56]. In these cases, the CT is typically ordered to help manage
the underlying medical condition and the guidelines for man-
aging that condition also suggest bone density testing due to
the medical condition itself or associated medications, either
of which is associated with deteriorated bone strength. For the
busy specialist physician and imaging-burdened patient typi-
cal of these medical conditions, ordering and undergoing
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opportunistic BCT may be less taxing and therefore more
appealing to both patient and provider compared to arranging
for and undergoing a separate DXA test. Early experience for
patients with inflammatory bowel disease indicates this oppor-
tunistic approach can indeed lead to greater compliance with
the clinical guidelines for bone testing [54].
Currently, opportunistic BCT is best suited for diagnostic
purposes as opposed to monitoring a patient’s response to
treatment. For the latter, detecting a statistically significant
treatment response—or a lack of response—over a 1–2-year
period for an individual patient requires the use of the same
acquisition settings and scanner manufacturer for the serial CT
scans. Because this is typically difficult to achieve for oppor-
tunistic BCT, we recommend that for patients tested by BCT
opportunistically, a baseline DXA could be ordered tomonitor
the treatment response. In this way, opportunistic BCT could
be used for diagnostic purposes and DXA for monitoring a
treatment response; if a patient tests negative by BCT, they can
be tested diagnostically again at some later time using either
BCT or DXA or any appropriate osteoporosis test.
Clinical efficacy and validation
In this section, we summarize the evidence supporting the
VirtuOst implementation of BCT. Key clinical points are first
presented, each of which is then justified by the accompany-
ing discussion. Additional support on each topic is presented
in a series of detailed appendices (see Supplementary
Materials).
The BMD measurements from BCT can be used
to identify osteoporosis and assess fracture risk using
traditional clinical guidelines and FRAX or other risk
calculators
One key issue when measuring BMD for clinical decision-
making is to ensure proper calibration of the CT scan, partic-
ularly with opportunistic BCT for which an external calibra-
tion phantom is not used. The VirtuOst implementation of
opportunistic BCT uses a patient-specific phantomless cali-
bration, in which the patient’s own internal tissues (e.g., blood,
visceral fat) and air—all assessed from the patient’s CTscan—
are used as calibrating references [32]. If there is excessive
image noise or metal artifact throughout these reference tis-
sues, the tissues cannot be used for internal calibration. As
discussed below, four blinded, prospective clinical studies
have reported the validity of this general approach for mea-
suring BMD [20, 32, 45, 47].
For the hip, BCT provides DXA-equivalent BMD T-scores
that can be used with the NHANES database of reference
values. The approach BCT uses for BMD T-scores is similar
to what is used by contemporary Lunar DXA machines, in
which Lunar-measured BMD values are mapped into
Hologic-equivalent values using empirical relations [57].
That mapping then enables the Hologic-measured young-ref-
erence values from the NHANES cohort to be used with a
Lunar DXA machine when calculating NHANES-
compatible T-scores—although the Lunar machine was not
used on the NHANES cohort. In the same way, when calcu-
lating T-scores, the BMD values from VirtuOst are mapped to
Hologic-equivalent values to enable use of the NHANES ref-
erence values.
To validate that approach for opportunistic BCT, hip areal
BMDT-scores derived separately from opportunistic BCTand
DXA were compared in two different studies in which the
BCT analyses were performed blinded to the DXA data. In
each study, the patients had both DXA and a pelvic-abdominal
CT exam as part of their routine clinical care—either a CT
enterography with intra-venous contrast (n = 65 men, 71
women; age 18–85 years) [45] or a low-energy CT
colonography without intra-venous contrast (n = 136 women;
age 43–92 years) [47]. In both studies, there was a high cor-
relation between the femoral neck BMD T-score as derived
from DXAversus BCT (R2 = 0.84) and good agreement in an
absolute sense as demonstrated by Bland-Altman analyses. In
the CT colonography study, for example, the BMD T-scores
for BCT agreed with DXA (both for the left hip) to the same
extent as did the BMD T-scores by DXA between the left vs.
right hips (Fig. 2). Further, in the colonography study, all eight
patients with BMD-defined osteoporosis by DXA had BMD-
defined osteoporosis by BCT (sensitivity 100%, specificity
98%) [47], as did six of the seven patients in the enterography
study (sensitivity 86%, specificity 97%) [45]. These collective
Table 2 Use of BCT in clinical
studies by related clinical
application
Study Sample size by sex Clinical application Type of CT scan
Weber 2014 [45] 71 F; 65 M Inflammatory bowel disease CT enterography
Maldonado 2019 [54] 135 F; 122 M Inflammatory bowel disease CT enterography
Fidler 2016 [47] 136 F Colorectal cancer screening CT colonography
Burch 2016 [55] 98 F Spine fusion Pre-operative spine CT
Schwaiger 2017 [56] 82 M Prostate cancer PET/CT
Adams 2018 [20] 1,922 F; 861 M Opportunistic screening Any hip-containing CT
F female, M male
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findings demonstrate that the femoral neck BMD T-scores for
BCT and DXA in real-world practice are statistically equiva-
lent. Other groups have also validated DXA-like hip areal
BMD measurements obtained from calibrated CT scans
[58–60]. At present, BCT only assesses one hip; it remains
to be seen if there is any clinical utility in assessing both hips.
As would be expected from this statistical equivalence, the
hip BMD T-scores from BCTand DXA have also been shown
to be equally effective for assessing fracture risk and
predicting hip fracture. Sampling from over 110,000 patients
who had both DXA and abdominal CTas part of their medical
care, the FOCUS study [20] determined the association be-
tween the hip BMD T-score (lower value from the femoral
neck and total hip regions), obtained from both BCT and
DXA, against the occurrence of new hip fractures subsequent
to the CTandDXA scans. The BCTmeasurements weremade
blinded to the DXA and fracture-outcome data. Results indi-
cated that for all the women tested with BCT in that study—
1019 with hip fracture and 903 without—the mean values of
the hip T-score from BCTand DXA differed by at most 0.1 T-
score unit. Further, the age-adjusted hazards ratio per standard
deviation deficit for hip fracture was the same for both modal-
ities (HR/SD = 2.1), as was the AUC (0.72). Consistent with
those metrics, at the traditional BMD T-score interventional
threshold of − 2.5, specificity for predicting new hip fracture
by the hip BMD T-score was the same for BCT and DXA
(0.77), and sensitivity was similar (0.56 BCT, 95% CI 0.51–
0.60; 0.52DXA, 0.47–0.56). For the men, the sensitivity (0.45
BCT vs. 0.43 DXA) and specificity (0.82 BCT vs. 0.83 DXA)
were similar between BCTand DXA, as was AUC (0.71 BCT
vs. 0.73 DXA). Finally, hazard ratio for hip fracture for those
testing positive by the BMD T-score criterion was statistically
similar for BCT and DXA, both for women (3.7 BCT vs. 2.9
DXA) and men (4.0 BCT vs. 3.3 DXA).
Because both DXA and BCT use the NHANES III refer-
ence populations for calculating the hip BMD T-scores, one
implication of these collective findings is that the clinical
guidelines for interpreting hip T-scores by DXA can also be
used for BCT; in addition, the BCT-derived femoral neck
BMD T-score can be used in lieu of the DXA BMD T-score
in FRAX [28] or other risk calculators.
As noted earlier, the spine BMD measurement for BCT is
not DXA-equivalent but instead is a volumetric BMD mea-
surement for the trabecular bone within one vertebral body,
thus avoiding many of the degenerative changes in the spine
that can confound a DXA-type BMD measurement. Obtained
for opportunistic BCT without an external calibration phan-
tom, these BMDmeasurements have been validated in a study
that directly compared them against paired measurements ob-
tained by traditional quantitative CT [32]. That study utilized
measurements derived from multiple clinical research studies
that used traditional quantitative CT (and an external calibra-
tion phantom). A paired comparison was made of data from
opportunistic BCT versus quantitative CT for 25 women and
15 men (age 41–86 years) scanned using 24 different CT
scanners (from four different CT manufacturers). Results in-
dicated a negligible difference (1 mg/cm3, not statistically sig-
nificant) between the two paired measurements and a high
correlation (R2 = 0.98, slope not different than unity); Bland-
Altman analysis also revealed no bias. These results establish
that the spinal volumetric trabecular BMDmeasurement from
opportunistic BCTwith internal tissue-based phantomless cal-
ibration is equivalent to that from traditional quantitative CT
with an external calibration phantom; a similar level of agree-
ment between the phantom and phantomless measurements
was found for all the BCT measurements [32].
The clinical use of vertebral trabecular BMD for osteopo-
rosis and vertebral fracture risk assessment, reported first in
the 1980s [61], is supported with BCT by its consistently high
association with vertebral fracture, using DXA as a reference.
For example, in all five of the vertebral fracture-outcome stud-
ies discussed below for BCT, age-adjusted odds ratios per
DXA: Hip vs. Spine HIP: DXA vs BCT Hip DXA: Left vs. Right
Fig. 2 Comparison of BCT vs. DXA for measuring the femoral neck
BMD T-score, with various DXA comparisons for reference. The
correlation between BCT and DXA (center) was similar to that between
left and right hip for DXA (right) and over twofold higher than between
hip and spine for DXA (left). From Fidler [47]
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standard deviation for vertebral fracture were consistently
higher for vertebral trabecular BMD than for spinal DXA
BMD, both for prevalent fracture—1.9 vs. 0.7 [62]; 1.9 vs.
1.3 [63]; 3.4 vs. 1.9 [64]—and for incident fracture—5.7 vs.
3.2 [33]; 2.4 vs. 1.8 [34]. Limited comparative data exist on
sensitivity and specificity for predicting new vertebral frac-
tures by vertebral trabecular BMD versus spinal DXA
BMD. As discussed below, the available comparative data
[33–35] suggest that the sensitivity for vertebral trabecular
BMD at the ACR-recommended (American College of
Radiology) cut-point of 80 mg/cm3 is higher than for spinal
DXA BMD T-score at the traditional T ≤ − 2.5 cut-point, al-
though specificity can be lower for BCT. Other groups previ-
ously validated vertebral trabecular BMD from quantitative
CT for vertebral fracture risk assessment [61]. Taken together,
these studies demonstrate that the vertebral trabecular BMD
measurement from opportunistic BCT is equivalent to that
from traditional quantitative CT, which in turn is at least as
good as spinal DXA-BMD for assessing vertebral fracture
risk.
BCT does not currently use any volumetric measurement
of BMD at the hip, in part because some fracture-outcome
studies have shown no advantage of doing so over traditional
hip BMD by DXA [65] and in part because interventional
thresholds for volumetric measurements of BMD at the hip
have not been established or validated.
Bone strength by BCT accurately measures bone
strength in human cadavers and has accurately
quantified treatment effects on bone strength
in monkeys
BCT is the only clinical test that non-invasively measures
bone strength—in units of force—for fracture risk assessment.
The bone strength measurement in BCTsimulates cadaver-lab
testing conditions, in which an excised bone is loaded to fail-
ure in a controlled orientation and configuration in order to
measure the breaking force (strength) of the bone. Extensive
literature reviews of BCT in general for bone strength assess-
ment are available elsewhere [24, 26]. For the VirtuOst imple-
mentation of BCT or its earlier versions, four studies have
reported on the accuracy of BCT-derived measurements of
bone strength, three studies addressing vertebral strength (for
a compressive overload) [33, 66, 67], and one addressing
femoral strength (for a sideways fall) [14]. All four studies
used laboratory-based biomechanical testing as the gold stan-
dard. As reviewed in detail in Appendix A, these human ca-
daver studies consistently demonstrated that BCT accurately
measured bone strength at the hip (sideways fall) and spine
(compressive overload) and that the directly measured
strength from biomechanical testing was more highly corre-
lated with BCT-measured bone strength than BMD (either by
DXA or quantitative CT) [14, 33, 66]. Consistent with these
results for VirtuOst, other groups using different
implementations of BCT have also reported correlations with
directly measured cadaver bone strength that were higher for
BCT-measured bone strength than BMD, both for the spine
[68–70] and hip [70–74].
All of these validation studies were done in human cadav-
eric specimens with limited information about prior medica-
tion use. To address the question of whether BCT measure-
ments are accurate in the setting of osteoporosis therapies, the
VirtuOst implementation of BCT was applied to non-human
primate bones with and without drug treatment (with
denosumab). In that study, BCTaccurately measured vertebral
strength both with and without drug treatment and with and
without ovariectomy [67]. Vertebral strength by BCT was
highly correlated with gold-standard biomechanical testing
(R2 = 0.97, n = 52 monkeys; Fig. 3), the relation being inde-
pendent of treatment (p = 0.12). Further, the magnitude of the
treatment effect of + 51% (95% CI 20–88%) observed with
BCT was just slightly numerically lower than the treatment
effect of + 57% (95% CI 26–95%) by biomechanical testing
(treatment effect estimated by comparing treated vs. untreated
groups). By contrast, the magnitude of the treatment effect by
bone mineral content and volumetric BMD of the vertebral
body was over twofold lower at 27% (95% CI 8–50%) and
28% (95% CI 14–45%), respectively.
In addition to demonstrating that BCTaccurately measured
the magnitude of the treatment-induced effects in bone
strength in this monkey model, these findings also demon-
strate the complexity of interpreting the magnitude of the
Fig. 3 Prospective validation of BCT (finite element analysis) for
measuring T12 vertebral strength in aged monkeys with and without
drug treatment, using direct mechanical testing as the gold standard.
BCT was performed blinded to the mechanical test results. Data are
color-coded by treatment group, for 52 monkeys, some treated with
denosumab or vehicle after ovariectomy, vs. sham (R2 = 0.97,
p < 0.0001; all data pooled); for reference, the dashed line shows the line
of unity. From Lee [67]
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treatment-induced changes in BMD or bonemass with respect
to actual changes in bone strength. For the monkey study, the
density/mass parameter that had a magnitude of effect most
similar to the observed change in bone strength was the
(volumetric) bone mineral content of the cortical shell and
its thickness, as measured by micro-CT analysis [67].
However, biomechanically, BCTalso showed that the strength
associated with the cortical and trabecular compartments
changed approximately equally [67]. It is not possible to di-
rectly validate these findings in humans. Short of that direct
validation, the data so far suggest that the main determinants
of treatment effects on strength—at least in the monkey model
and for treatment with denosumab—are those that were ade-
quately captured by BCT, namely, the bone geometry and
mass and the spatial distribution of bone mass. Those findings
in turn imply that any potential molecular or other lower-scale
effects of the treatment in that monkey study did not play any
appreciative role in the strength response. A similar trend was
observed in a finite element analysis study of the distal radius
in monkeys treated with odanacatib [75]. If molecular or
small-scale treatment effects are also unimportant after treat-
ment with contemporary osteoporosis agents in older humans,
these collective human cadaver and monkey validation studies
suggest that BCT may capture the correct magnitude of treat-
ment effects on bone strength in humans.
Bone strength by BCT is associated with risk of hip,
spine, and major osteoporotic fractures at least
as strongly as is BMD by either DXA or quantitative
CT, for both sexes
Nine clinical fracture-outcome studies have been performed to
date for BCT using VirtuOst. Involving both women and men,
three studies addressed prevalent spine fracture, two ad-
dressed incident spine fracture, two addressed incident hip
fracture, one addressed both incident spine and hip fractures,
and one addressed any prevalent major osteoporotic fracture
(clinical spine, hip, proximal humerus, or wrist). Together,
these studies involved BCT measurements taken in over
5500 subjects, sampled using case-control or case-cohort de-
signs from much larger study populations. In all instances, the
BCT analyses were performed blinded to the fracture out-
comes. Details of the studies and cohorts are provided in
Appendix B. Overall, the combined cohorts represented both
sexes, populations in both the USA and Europe, with one
large US cohort [20] including both sexes and being racially
diverse.
Across all nine studies, low values of bone strength were
consistently associated with an increased risk of fracture, in-
cluding hip, spine, or any osteoporotic fracture, for both sexes
(Table 3; Fig. 4). As a reference for interpretation, results for
bone strength by BCT in these studies can be compared with
those for BMD, usually by DXA (or CT-based DXA-
equivalent measurements). As noted elsewhere [77], an in-
crease in the hazards or odds ratio (divided by the population
standard deviation of the measurement) typically improves
sensitivity for fracture prediction without markedly affecting
specificity, although, as noted below, sensitivity and specific-
ity data comparing both BCTand BMD are sparse. We did not
perform a statistical meta-analysis of these data, which was
beyond the scope of this review. However, collectively in 13
of the 14 comparisons of fracture outcomes made in these nine
studies, the published data for each individual study indicate
that bone strength had either a statistically stronger or numer-
ically higher association with fracture than did BMD, as quan-
tified by the age-adjusted hazard or odds ratio (divided by the
standard deviation); the other single comparison showed an
almost identical association. For example, across studies, the
hazard or odds ratio per SD for spine fracture ranged from 1.7
to 7.2 for vertebral strength and from 0.7 to 3.2 for BMD and
for hip fracture ranged from 3.0 to 8.0 for femoral strength and
from 2.3 to 4.6 for BMD (Table 3; Fig. 4). Taken together,
these data indicate that the association of bone strength with
risk of hip or spine fractures equals or exceeds that of BMD by
either DXA or quantitative CT.
In eight of these nine studies, BCT was performed at the
same general anatomic site (hip or spine) as the site of the
outcome fracture (hip or spine fracture, respectively). In the
other study, hip BCT was used to assess risk of any major
osteoporotic fracture [76]. That study demonstrated that fem-
oral strength by hip BCTwas associated with any (prevalent)
major osteoporotic fracture, performing as well as DXA-
equivalent hip BMD (by BCT). In particular, the age-
adjusted odds ratio of a major osteoporotic fracture was at
least as high for femoral strength as for the hip BMD (by
BCT), both for both women [odds ratio (95% CI)—bone
strength 1.8 (1.1–2.9) vs. hip BMD 1.5 (1.1–1.9)] and men
[bone strength 3.2 (1.7–6.2) vs. hip BMD 2.0 (1.3–3.0)].
These collective data indicate that the odds or hazard ratio
(per standard deviation) trended consistently higher for bone
strength than BMD. Presumably, this trend reflects that a
greater portion of the variation across the population in true
bone strength—which directly influences fracture risk—is
captured by the BCT measurement of bone strength than by
BMD. Across large groups of individuals, the relative varia-
tion (ratio of standard deviation to mean value) for both fem-
oral [20] and vertebral [63] strength by BCT is up to twofold
greater than the relative variation for BMD, particularly for
areal BMD. This greater relative variation for strength partly
reflects the non-linear relation between bone strength and
BMD at the tissue level; it also partly reflects other factors
that affect whole-bone strength independently of BMD and
that also vary across the population, for example, cortical
thickness, overall bone shape and geometry, and spatial distri-
bution of BMD within the bone including the relative amount
of cortical and trabecular bone—all of which are captured to
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some degree and mechanistically within the BCT model but
are missed by the DXA BMD measurement. For the same
reasons, a simultaneous variation of these other factors over
time also explains why typical age-related declines are
thought to be greater (percent-wise) at the whole-bone level
for bone strength than for BMD [78]. As discussed next, in-
tegration of these same factors in the BCT model likely ex-
plains why bone strength by BCT has been shown to predict
fracture independently of BMD.
Bone strength by BCT is associated with fracture risk
independently of BMD by DXA
The large FOCUS study provided definitive evidence on this
issue regarding hip fractures, for both sexes. That study drew
from an underlying population of 111,694 patients age 65 or
older with an abdominal or pelvic CTand a DXA examwithin
3 years of the CTand no prior hip fracture. Cases were defined
as those who subsequently suffered a hip fracture (1340 wom-
en, 619 men) and controls (no fracture) were randomly select-
ed subgroup from the overall cohort (1350 women, 629 men),
after removing any participants with hip fracture. As noted
above, this study confirmed the equivalence of the hip T-
score (using the lower T-score from the femoral neck and total
hip regions) as measured by BCT versus DXA. This equiva-
lence justified using logistic regression to directly compare
paired measurements of the hip BMD T-score (from BCT)
and bone strength, both measurements taken from the very
same CT scan and thus minimizing any random errors associ-
ated with variations in imaging parameters or any time differ-
ence between the CT and DXA scans.
FOCUS established that incident hip fracture was associat-
ed with femoral strength independently of hip BMD. In par-
ticular, after adjusting for age, BMI, race/ethnicity, and the hip
BMD T-score (lower T-score from femoral neck or total hip
regions, fromBCT), the age-adjusted hazard ratio per standard
deviation for femoral strength was statistically significant for
both women (HR = 1.9, 95% CI 1.2–3.1) and men (HR = 3.4,
95% CI 1.6–7.2). Consistent with these findings, the earlier
but smaller Age, Gene/Environment Susceptibility (AGES)
study of hip fracture (108 fracture cases for women, 63 for
men) also used logistic regression to show that femoral
strength was associated with incident hip fracture indepen-
dently of femoral neck areal BMD (by BCT) for women
(p = 0.01) and independently of total hip areal BMD for both
Table 3 Summary of studies comparing fracture risk assessment between BMD and bone strength
Study by fracture site Demographic N fracture/no-fracture, sex (N = 5514 total) Age-adjusted HR (per SD) or OR (95% CI)
BMD Bone strength
Vertebral fracture (BCT/DXA measurements made at the spine):
Melton 2007 [62]† 40/40 F 0.7 (0.4–1.2) 2.2 (1.2–4.3)
Melton 2010 [63]† 193/90 F 1.3 (1.1–1.6) 1.7 (1.4–2.1)
Wang 2012 [33] 63/243 M 3.2 (2.0–5.2) 7.2 (3.6–14.1)
Anderson 2014 [64]† 40/80 F/M 1.9 (1.1–3.3) 3.0 (1.4–6.9)
Kopperdahl 2014 [35] 117/380 F 2.3 (1.7–3.2)†† 2.8 (1.8–4.3)
50/296 M 1.7 (1.2–2.5)†† 2.2 (1.5–3.2)
Allaire 2018 [34] 26/62 F/M 1.8 (1.0–3.3) 3.8 (1.5–9.2)
Hip fracture (BCT/DXA measurements made at the hip):
Orwoll 2009 [16] 40/210 M 4.6 (2.6–8.3) 8.0 (2.6–24.3)
Kopperdahl 2014 [35] 108/500 F 2.7 (1.9–3.9) 4.2 (2.6–6.9)
63/377 M 3.7 (2.5–5.6) 3.5 (2.3–5.3)
Adams 2018 [20]§ 595/769 F 2.3 (1.9–2.9) 3.6 (2.8–4.6)
308/404 M 2.4 (1.9–3.1) 3.0 (2.2–4.3)
Any major osteoporotic fracture (BCT/DXA measurements made at the hip):
Amin 2011 [76]† 55/175 F 1.5 (1.1–1.9) 1.8 (1.1–2.9)
28/162 M 2.0 (1.3–3.0) 3.2 (1.7–6.2)
Incident (new) fractures unless noted otherwise; BMD is measured by DXA (or is DXA-equivalent) unless noted otherwise; bone strength is measured
by VirtuOst or earlier implementations
F female, M male
† Prevalent (existing) fracture (occurred before the imaging)
††Vertebral trabecular volumetric BMD by quantitative CT (spine BMD by DXA not measured in those studies)
§ Results are reported here for patients not recently treated with any osteoporosis medication
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sexes (women p = 0.0006, men p = 0.0001) [35]. Previously,
the slightly smaller Osteoporotic Fractures in Men (MrOS)
study of hip fracture in men (n = 40 hip fractures) [16] did
not show a significant independent association of femoral
strength over hip BMD (HR = 2.7, 95% CI 0.5–14.6).
However, the effect size in that study (HR = 2.7) is similar to
that observed for men in the larger FOCUS study (HR = 3.4),
suggesting the lack of statistical significance in the MrOS
study was due to low statistical power.
Evidence also shows that vertebral strength is associated
with risk of incident spine fracture independently of BMD by
either spine or hip DXA. For the MrOS study of elderly men
with clinically apparent new vertebral fractures (n = 63 frac-
tures) [33], the age-adjusted hazard ratio per standard devia-
tion deficit for vertebral compressive strength (7.2; 95% CI
3.6–14.1) was over twofold higher (p < 0.005) than for DXA
lumbar spine BMD (3.2, 2.0–5.2) and was fourfold higher
than for femoral neck BMD (1.8, 1.2–2.9). Further, vertebral
strength was associated with vertebral fracture independently
of DXA spinal BMD (p < 0.001) and its hazard ratio was
numerically higher than for volumetric BMD of the entire
vertebral body by quantitative CT (“integral BMD,” 5.7,
3.1–10.3). In a more recent but smaller study of incident ver-
tebral fracture in both sexes (13 men and 13 women with
fracture) [34], vertebral strength was associated with fracture
independently of a research-only measurement of DXA-
equivalent spinal BMD (age-adjusted odds ratio 5.1, 95% CI
1.5–17) and also had better prediction (AUC = 0.80 vs. 0.72,
p = 0.05). The AGES study of incident vertebral fracture in
Iceland (n = 117 women and n = 50 men with fracture) did not
include DXA but did include volumetric trabecular BMD by
quantitative CT. Consistent with the findings from MrOS for
clinical vertebral fractures in men, vertebral strength was as-
sociated with fracture independently of volumetric BMD for
the men (p < 0.01), and the combination of vertebral strength
and vertebral trabecular volumetric BMD significantly im-
proved (p < 0.006) the net fracture classification index for
moderate/severe grade incident vertebral fractures in men. In
that study, no significant improvement for vertebral strength
over volumetric BMDwas observed for predicting less severe
vertebral fractures or for women, but the age-adjusted odds
ratios per standard deviation all trended higher for vertebral
strength than for volumetric BMD for both sexes and all frac-
ture grades (e.g., 4.3 vs. 3.1 for women, 2.4 vs. 1.4 for men,
for more severe fractures). Taken together, this body of evi-
dence suggests that vertebral strength is associated with risk of
incident spine fracture independently of BMD by DXA, with
a slightly stronger association than seen for volumetric BMD
Fig. 4 Graphic depiction of the age-adjusted hazard ratio (per standard
deviation change) or odds ratio values, taken from Table 3, for hip and
spine measurements, grouped by sex, for predicting fracture [study cita-
tions]. For the hip measurement, the outcome was incident (new) hip
fracture, unless noted otherwise as prevalent (existing) MOF (major
osteoporotic fracture). For the spine measurement, the outcome was inci-
dent vertebral fracture, unless noted otherwise as prevalent. BMD either
by DXA or DXA-equivalent, unless noted (double dagger denotes tra-
becular BMD from quantitative CT). Error bars show the reported 95%
confidence intervals (see Table 3 and Appendix B for details)
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by quantitative CT. For prevalent fracture, the association with
fracture is similar between vertebral strength and volumetric
BMD, both of which consistently have stronger associations
than DXA BMD [62–64].
Older patients classified by BCT as having either
BMD-defined osteoporosis or fragile bone strength
are at high risk of fracture
Although fracture risk in older individuals depends on many
factors, almost all clinical decision-making for considering
therapeutic treatment ultimately classifies the individual pa-
tient into a “high-risk” category using some type of interven-
tional threshold. For example, the DXA BMD T-score thresh-
old of − 2.5 at the hip or spine is widely used to identify
candidates for treatment. Likewise, in the USA, the 3% thresh-
old for 10-year absolute risk of hip fracture from the FRAX
calculator is also used to identify high-risk patients suitable for
treatment [46, 79]. Research on optimal ways to identify high-
risk patients using some type of threshold or risk-based ap-
proach, and how to best incorporate strength measurements, is
ongoing in the field.
For BCT, the FDA-approved interventional thresholds for
fragile bone strength using VirtuOst, first reported in 2014
[35], were developed with clinical decision-making in mind
and have been validated in a number of studies (for details on
the development, see Appendix C). To validate that patients
classified by BCTas having fragile bone strength are indeed at
clinically significant high risk of fracture—and therefore can-
didates for treatment—comparisons of sensitivity (and speci-
ficity) for predicting new fractures via fragile bone strength by
BCT can be compared with sensitivity (and specificity) via
BMD-defined osteoporosis by DXA, the clinical standard of
care (or DXA-equivalent hip BMD from BCT); alternatively,
the observed probability of fracture in these studies can also be
compared at the interventional thresholds for fragile bone
strength versus BMD-defined osteoporosis, again interpreting
the latter as a reference standard. Two such studies addressed
new hip fractures [20, 35], two addressed new spine fractures
[34, 35], and two earlier studies also provide support when
considered in retrospect [16, 33]; details of all studies are
provided in Appendix C. Collectively, the available data dem-
onstrate that older patients classified by BCTas having fragile
bone strength, at the hip or spine, are at clinically significant
high risk of fracture.
As regards to identifying patients at high risk of hip fracture,
the FOCUS study assessed both risk of fracture at the interven-
tional thresholds and sensitivity (and specificity) [20]. Risk of hip
fracture was numerically higher for the women and men who
tested positive with fragile bone strength by BCT than for those
testing positive with BMD-defined osteoporosis either by hip
DXA or by traditional DXA (hip/spine), the difference against
traditional DXA reaching statistical significance for the women,
and AUC values for femoral strength were similar to those from
the DXA BMD T-score (within 0.10 points). Considering sensi-
tivity and specificity, for the women in the FOCUS study, sensi-
tivity for predicting incident hip fracture at 5 years was signifi-
cantly higher for fragile bone strength at the hip by BCT (0.63,
0.59–0.68) than for BMD-defined osteoporosis at the hip by
DXA (0.52, 0.47–0.56), although specificity was significantly
lower for fragile bone strength (0.69, 0.64–0.74) than for
BMD-defined osteoporosis (0.77, 0.73–0.81). For men, sensitiv-
ity trended numerically higher for fragile bone strength at the hip
(0.48, 0.42–0.55) than for BMD-defined osteoporosis at the hip
by DXA (0.43, 0.37–0.50), with similar specificities (0.82 vs.
0.83, respectively). In typical clinical practice, one would use
the lower BMD T-score from the hip or spine when using
DXA to identify patients with BMD-defined osteoporosis [46].
Doing so in FOCUS yielded a sensitivity for BMD-defined os-
teoporosis for women that increased from 0.52 to 0.59—numer-
ically lower than 0.63 for fragile bone strength—while specificity
decreased from 0.77 to 0.67—also numerically lower than 0.69
for fragile bone strength. As described in more detail in
Appendix C, in the AGES study of incident hip fractures in
women and men in Iceland [35], the elevated probability of
fracture at the interventional thresholds was statistically similar
for fragile bone strength versus BMD-defined osteoporosis at the
hip, and retrospective evidence of higher sensitivity at equivalent
specificity for fragile bone strength at the hip over BMD-defined
osteoporosis at the hip was reported in the MrOS study of hip
fractures in elderly men [16].
The FOCUS study extended these results by showing that
when both femoral strength and hip BMD from BCTare used
to identify high-risk patients—as opposed to using just femo-
ral strength or just BMD—BCT at the hip correctly identified
more patients at high risk of hip fracture than did traditional
(hip/spine) DXA, and those patients testing positive with hip
BCT were at higher risk of hip fracture than those testing
positive by traditional DXA [20]. Consistent with that finding,
in the earlier AGES study, reclassification analysis indicated
that prediction of hip fracture for women was improved by
considering both femoral strength and hip BMD (p = 0.002)
[35].
Considering measurements of both femoral strength and
hip BMD can facilitate clinical interpretation since it enables
physicians to easily identify patients with clinically significant
low levels of bone strength in the absence of BMD-defined
osteoporosis. In doing so, one approach is to identify high-risk
patients as those who test positive by BCT for either fragile
bone strength or BMD-defined osteoporosis. Using this
either/or approach in the FOCUS study, sensitivity for
predicting 5-year hip fracture increased (0.63 to 0.66 for wom-
en; 0.48 to 0.56 for men) and specificity decreased (0.69 to
0.66 for women; 0.82 to 0.76 for men) compared to using only
bone strength, and AUC values did not change. For clinical
reference purposes, when comparing this approach for hip
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BCT against traditional DXA (lowest T-score at the hip or
spine), sensitivity for BCT was 12% higher for women (0.66
vs. 0.59) and 17% higher for men (0.56 vs. 0.48) than for
traditional DXA, with similar values of specificity between
hip BCT used in this way and tradit ional DXA.
Furthermore, the women who tested positive by BCT in this
way were at over 50% higher elevated risk of hip fracture than
were those women testing positive by traditional DXA (haz-
ard ratio 3.4 vs. 2.2, p < 0.05); there was no significant effect
for men (hazard ratio 4.0 BCT vs. 3.3 DXA). Studies have not
yet been performed to assess whether hip fracture prediction is
improved for BCT by combining BCT measurements at the
spine and hip. Nevertheless, these findings demonstrate that
older patients classified by hip BCT as having either fragile
bone strength or BMD-defined osteoporosis (by BCT) are at
clinically significant high risk of hip fracture.
As regards to identifying patients at high risk of spine frac-
ture, fewer data exist. As described inmore detail in Appendix
C, in the AGES study of incident vertebral fractures in women
and men in Iceland [35], the elevated probability of fracture at
the interventional thresholds was statistically similar for frag-
ile bone strength versus BMD-defined osteoporosis at the
spine; sensitivity and specificity were not reported. In the
small Framingham study of women and men (26 incident
fracture cases) [34], fragile bone strength at the spine trended
toward twofold higher sensitivity than a validated DXA-
equivalent spine T-score (from quantitative CT) for identify-
ing new vertebral fracture (0.46 vs. 0.23, p = 0.09), at similar
values of specificity. Consistent with these findings, in the
earlier and larger (n = 63 incident fracture cases) MrOS study
of clinical spine fractures in elderly men [33], low values of
vertebral strength produced higher sensitivity than did the
established spinal DXAT-score thresholds, at the same spec-
ificity. The interventional thresholds for fragile bone strength
had not been established at the time of that study. Even so,
sensitivity trended higher for strength both at 95% specificity
(37% BCT vs. 30% DXA) and at 90% specificity (52% BCT
vs. 43% DXA), and AUC was higher (0.83 BCT vs. 0.76
DXA, p < 0.02).
BCT measurements are precise and clinically
reproducible
Opportunistic BCT uses the patient’s internal tissues as
“phantomless” calibrating references; it also utilizes CT scans
from a variety of different CT scanners and acquisition set-
tings. One potential concern with opportunistic BCT is the
measurement error associated with the use of different CT
scanners or scan acquisitions—how robust are one-time mea-
surements used for diagnostic purposes? To date, two studies
have been reported that are relevant to measurement precision
and clinical reproducibility for opportunistic BCT (performed
at the O.N. Diagnostics centralized BCT facility).
For inter-operator precision, one study was performed on
25 women and 15 men (age range, 41–86 years) who
underwent CT scanning on 24 different CT scanners (four
different CT manufacturers) as part of different clinical drug
trials (baseline scans only, no drug treatment); scans were re-
analyzed by two different BCT technicians who were blinded
to each other [32]. Results indicated that the reanalysis preci-
sion errors (CV%) for all measurements of bone strength and
BMD by opportunistic BCT (i.e., using phantomless calibra-
tion), at the hip and spine, were 0.5% or less. Thus, for the
same scan analyzed by different BCT technicians, inter-
operator discordance was negligible.
To assess clinical reproducibility, one must account for the
typical uncertainty associated with the variability of the source
scan, both in CT scanner and the acquisition settings, and
patient repositioning. Data from one study can be used to
address this issue [56]. That study reported on men with pros-
tate cancer (n = 82, 71.6 ± 8.3 years) who underwent both
PET/CT and multi-detector CT at different time points as part
of their medical care—two very different types of CT scan.
Both the BMD and bone strength measurements at the hip and
spine were directly compared between the paired PET/CT
(one scanner) and multi-detector CT (12 different scanners)
scans, taken in a clinical setting within 3 months of each other
(full paired data were available for n = 63 patients). Results
indicated that the mean paired differences (p > 0.05 unless
noted) between the various BCT measurements for the two
types of scan were all small: 1.1% for total hip areal BMD,
1.3% femoral strength, 2.6% for vertebral trabecular
BMD,1.7% for vertebral strength, and 2.5% (p = 0.007) for
femoral neck areal BMD. Consistent with these small differ-
ences, between-scan agreement for fracture-risk classification
was 97% (0.89 kappa for repeatability). Comparable differ-
ences have been noted between different types of DXA scan-
ners for the BMD T-score [80]. For example, for the femoral
neck BMD T-score, which can be directly compared between
BCT and DXA, the correlation between measurements within
each modality was at least as high for BCT (R2 = 0.94; PET/
CT vs. multi-detector CT) as for DXA (R2 = 0.87; Hologic
DXAvs. Lunar DXA). These findings suggest that the clinical
reproducibility for one-time measurements for opportunistic
BCTwhen used on different scanners/settings should be com-
parable to reproducibility for DXA when used on different
scanners.
Non-opportunistic BCT can be used to monitor
for a treatment response
“Monitoring” in osteoporosis care typically refers to measur-
ing or confirming a treatment-induced response over time,
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which can be challenging clinically. One challenge is that
annual percent changes in bone strength (and BMD) for the
individual patient are often comparable to measurement pre-
cision errors [81], and changes may be even smaller if the
patient is on an antiresorptive treatment. Another challenge
is that, for maximum measurement precision, the imaging
equipment and protocol should remain unchanged across all
serial measurements. Since those latter conditions are difficult
to achieve for opportunistic BCT, and since opportunistic
BCT has not yet been characterized for monitoring treatment
responses in individual patients, monitoring of a treatment
response for an individual patient is not currently recommend-
ed with opportunistic BCT. However, as discussed next, the
evidence so far suggests that when BCT is used non-
opportunistically, that is, with a dedicated CT scan and a tra-
ditional calibration phantom, and when the imaging
equipment and protocol remains unchanged across all serial
measurements, then BCT is an excellent modality for moni-
toring treatment responses in individual patients and may de-
tect changes missed by DXA.
The ability of non-opportunistic BCT to detect treatment
responses is evident from multiple clinical research studies
that assessed various types of treatment in which both BCT
and DXA were used for monitoring. Using VirtuOst or its
earlier implementations, 13 such clinical studies have been
reported, involving over 1600 subjects (Table 4).
Collectively, these studies demonstrate that loss of bone at
the hip or spine in placebo groups can be detected earlier
and is statistically more significant by BCT than by DXA
(Fig. 5; see further details in Appendix D). Furthermore, some
BCT studies have shown statistically significant changes in a
strength-to-density ratio after drug treatment [82, 88, 89].
Table 4 BCT monitoring studies (13 total) for drug or other treatments. Non-opportunistic BCTwas performed at the hip (H) or spine (S) or at both
sites. N = 1644 subjects total, over all studies. Details of the studies in italicized entries are discussed in Appendix D
Study Age (years)
mean ± SD
Number Hip or spine assessed Treatment
Keaveny 2007 [82] 62.5 ± 1.6 25 S Alendronate
64.5 ± 1.4 28 S Teriparatide
Mawatari 2008 [83] 62.7 ± 2.2 15 S Control (non-antiresorptive)
60.4 ± 2.9 14 S Alendronate
Keaveny 2008 [84] 55–85 72 H PTH(1–84)
55–85 42 H Alendronate
55–85 37 H PTH(1–84) and alendronate
Lewiecki 2009 [85] 63.5 ± 6.0 46 H + S Placebo
64.8 ± 7.2 47 H + S Ibandronate
Keaveny 2012 [86] 64.2 ± 7.7 27 H Teriparatide
62.2 ± 8.4 21 H Alendronate
Brixen 2013 [87] 64.0 ± 6.2 105 H + S Placebo
63.9 ± 7.3 109 H + S Odanacatib
Cosman 2013 [88] 67.9 ± 1.3 43 H + S Raloxifene, add teriparatide
68.6 ± 1.3 44 H + S Raloxifene, switch to teriparatide
67.1 ± 1.3 46 H + S Alendronate, add teriparatide
69.3 ± 1.2 49 H + S Alendronate, switch to teriparatide
Keaveny 2014 [31] 74.1 ± 6.0 48 H + S Placebo
73.3 ± 4.2 51 H + S Denosumab
Kleerekoper 2014 [89] 62 ± 8 34 H + S Teriparatide
Snyder 2017 [90]† 72.4 ± 5.5 101 H + S Placebo
72.3 ± 6.3 110 H + S Testosterone
Keaveny 2017 [91] 64.3 ± 4.7 24 H + S Romosozumab
65.8 ± 5.7 31 H + S Teriparatide
66.1 ± 5.8 27 H + S Placebo
Langdahl 2017 [92] 71.8 ± 7.4 218 H Romosozumab (prior bisphosphonate)
71.2 ± 7.7 218 H Teriparatide (prior bisphosphonate)
Howe 2019 [93] 56–89 12 H AGN1 LOEP
VirtuOst or a related software implementation of BCT was used in all studies
†Women in all studies except Snyder [90], in which only men were assessed
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Those findings suggest that treatment-induced responses in
BMD and strength can sometimes differ. Finally, the monkey
study of denosumab discussed above showed that the magni-
tude of treatment-induced change in directly measured verte-
bral strength was correctly captured by BCT but not by overall
BMD or bone mineral content [67]. Thus, in the context of
fracture risk, BCT-measured strength responses may be easier
to interpret than BMD responses.
Opportunistic BCT may be cost-effective compared
to usual-care DXA screening
To quantify the potential clinical impact of opportunistic BCT
for the CT-patient, a theoretical cost-effectiveness study [94]
simulated a hypothetical cohort of 1000 Medicare patients
who had undergone an abdominal CT for any medical indica-
tion but were without a recent DXA. All those “DXA-lacking”
CT patients were offered BCT, 90% were successfully tested,
and 50% of those who tested positive took generic alendronate
for 2 years; hip fractures were then tracked over 5 years. That
group was compared to usual care treatment for those patients:
instead of being offered BCT, these hypothetical patients were
tested annually with DXA at typical Medicare testing rates
(9.5% for women, 1.7% for men [4]); and, like BCT, 50% of
positive-testing patients were then treated with alendronate for
2 years. For both groups, over the 5-year observation period,
patients were not monitored with any additional tests.
Sensitivity and specificity for BCTand DXAwere taken from
the FOCUS real-world study [20].
For women, the results indicated that BCT testing would
prevent over twice as many hip fractures and increase quality
adjusted life years (QALY) almost fourfold, compared toman-
aging these patients instead by usual-care DXA testing. The
absolute benefit was greater in women but the relative benefit
was greater in men (Fig. 6). The clinical efficacy increased
further if more than 50% of positive-testing patients went on
Fig. 5 Percent change (mean ± SE) from baseline, 6–24 months, in BMD by DXA and bone strength by BCT at the spine and hip in postmenopausal
women treated with odanacatib (X) or placebo (O). Adapted from Brixen [87], with axes scaled for uniformity
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treatment, if treatment was extended beyond 2 years, or if the
BCT program was restricted to higher risk (e.g., older) pa-
tients. Likewise, clinical efficacy decreased if fewer than
50% of positive-testing patients went on treatment or if treat-
ment only lasted for 1 year. These findings suggest that BCT,
if widely implemented within a healthcare setting, could be
cost-effective compared to usual-care DXA testing and in
some circumstances may be cost saving. However, different
healthcare systems and countries can have different clinical
guidelines and payment and coverage policies for osteoporo-
sis screening, which would be an additional issue to consider
in assessing potential impact, cost-effectiveness, and feasibil-
ity of opportunistic BCT. Other groups have reported that
BCT can also be cost-effective in certain circumstances even
when BCT is used non-opportunistically with a dedicated CT
scan [25, 95]. Despite the predictions of all these theoretical
analyses, until implemented in practice in different settings,
true efficacy and cost-effectiveness for BCT cannot be deter-
mined with certainty.
Summary and discussion
Diagnostic screening for osteoporosis is critical for primary
fracture prevention since it is the gateway to treatment [8, 46].
Osteoporosis is a condition of compromised bone strength
leading to increased risk of fracture. Long and widely used
for research purposes [14, 16, 35, 50, 71, 72, 96–110], BCT—
aka finite element analysis of clinical-resolution CT scans—is
well established for providing non-invasive measurements of
bone strength [23–26]. Clinically, BCT is now a Medicare
screening benefit in the USA, providing diagnostic-quality mea-
surements of both bone strength andBMD fromCTscans.When
used opportunistically, and unlike simpler opportunistic analyses
of previously taken CTscans [111], themeasurements fromBCT
can be used to identify osteoporosis and assess fracture risk and
do not need confirmation by DXA. In that context, we reviewed
the clinical evidence supporting opportunistic BCT, focusing on
the VirtuOst implementation of BCT because it is the only FDA-
cleared implementation of BCT available for patient care in the
USA. With a clinical focus in mind, the body of evidence
reviewed here supports the following:
& The BMD measurements from BCT can be used to iden-
tify osteoporosis and assess fracture risk using traditional
clinical guidelines and FRAX or other risk calculators.
& Bone strength by BCT accurately measures bone strength
in human cadavers and has accurately quantified treatment
effects on bone strength in monkeys.
& Bone strength by BCT is associated with risk of hip, spine,
and major osteoporotic fractures at least as strongly as by
BMD by either DXA or quantitative CT, for both sexes.
& Bone strength by BCT is associated with fracture risk
independent of BMD by DXA.
& Older patients classified by BCT as having either BMD-
defined osteoporosis or fragile bone strength are at high
risk of fracture.
& BCT measurements are precise and clinical ly
reproducible.
& Although BCT can be used to monitor for a treatment
response when the CT scan is obtained specifically for
bone strength purposes, the major current clinical applica-
tion of BCT is likely its opportunistic use. In this setting,
monitoring for a treatment response by BCT is not cur-
rently recommended.
& Opportunistic BCT may be cost-effective compared to
usual-care DXA screening.
Fig. 6 Clinical utility of BCT and usual-care DXA testing versus no care. From Pisu [94]
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When utilizing hip-containing CT exams of the abdomen
or pelvis, BCT performed at the hip is particularly effective for
identifying patients at high risk of hip fracture. With about
seven million CT exams of the abdomen or pelvis being per-
formed each year in the US Medicare population [27], oppor-
tunistic BCT at the hip should help improve osteoporosis care
for this population and may do so in a cost-effective manner
compared to usual care DXA testing [94]. For non-CT pa-
tients, DXA testing remains appropriate as per current guide-
lines, unless there are specific reasons to order a BCT with a
dedicated CT—patients presenting without BMD-defined os-
teoporosis but with an otherwise unexplained fracture or pa-
tients with appreciable vertebral degeneration [55] or aortic
calcification [47]. Others have reported that BCT may also
be cost-effective in some situations when used for screening
with a dedicated CT [25, 95].
A key issue in using BCT to manage patients is the validity
and robustness of the interventional thresholds used for clini-
cal decision-making. As reviewed here, the BCT intervention-
al thresholds for both BMD and bone strength as measured by
VirtuOst have been prospectively validated in a number of
studies. Those studies were performed in the USA in racially
[20] and geographically [16] diverse populations, in Iceland
for a mostly Caucasian population [35], and for both sexes.
Interestingly, preliminary data suggest that the bone strength
thresholds used so far for BCT in the USA and Europe may
also apply to native Koreans—because the relationship be-
tween BMD and bone strength appears to be uniform between
Koreans and Caucasians [112], although fracture outcomes in
these populations have not yet been assessed using these
thresholds. In terms of robustness, the centralized laboratory
delivery model for BCT—which can reach patients
remotely—is designed to ensure quality and consistency of
the BCT results, much like centralized laboratory services
for blood and genetic tests. Thus, the BCT results via that
delivery model should be sufficiently consistent and robust
for clinical decision-making regardless of geographic
location.
Despite the patient-convenience of opportunistic BCT,
there are some logistical challenges for its current delivery
model via a laboratory-based service. The associated clinical
workflow is unique and may be challenging to widely imple-
ment, at least initially. For example, while BCT is now clini-
cally available in the USA, its availability must meet patient
privacy and HIPAA requirements and is currently limited to
early-adopter healthcare providers. Internationally, there may
be legal or patient-privacy barriers that prevent transmission
of CT scans across national borders, perhaps requiring
country-specific implementation. It is possible in the future
that BCT becomes available for individual healthcare pro-
viders to perform locally without the need to transfer CT
scans; for that scenario, issues of robustness, quality control,
and standards may become more relevant. At present, while
the test is now covered and reimbursed by Medicare in the
USA, due to its novelty, it will take time for healthcare pro-
viders to integrate BCT into its workflow and reimbursement
payment pathways and for private insurers to set policy and
payment rates for the test.
When using BCT clinically, physicians will occasionally
encounter a patient who does not have BMD-defined osteo-
porosis but has fragile bone strength—are these patients good
candidates for treatment? For example, Fig. 7 shows a subset
of women and men in the AGES study from Iceland who were
at high risk of a new hip fracture due to having fragile bone
strength at the hip but without having BMD-defined osteopo-
rosis at the femoral neck. Using just hip BCT measurements,
the data reviewed here from the FOCUS and AGES studies
established that women who test positive for fragile bone
strength are at as high a risk of fracture as are those who test
positive for BMD-defined osteoporosis by hip DXA, and
Fig. 7 Example of older women (top) and men (bottom) at high risk of
fracture due to fragile bone strength but without BMD-defined osteopo-
rosis at the femoral neck. The gray box contains all new hip fracture cases
(open circles) who had fragile bone strength without BMD-defined oste-
oporosis at the femoral neck; plots taken directly from the AGES study of
incident hip fracture in women and men in Iceland [35]. Note, few indi-
viduals in this study had BMD-defined osteoporosis at the femoral neck
without fragile bone strength
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FOCUS further established that these patients have about the
same prevalence but are at higher risk of fracture than those
testing positive by traditional hip/spine DXA. The issue then
arises as to whether or not to treat such patients. As noted
above, true osteoporosis is defined as “a skeletal disorder
characterized by compromised bone strength, predisposing
to an increased risk of fracture” [1, 2]. By that definition,
patients with fragile bone strength have osteoporosis and
should be considered for treatment. Consistent with this con-
cept, current clinical practices already embrace identifying
high-risk patients who present with BMD-defined osteopenia
but who have other signs of compromised bone strength that
place them at high risk of fracture. For example, one or more
existing fractures in the absence of BMD-defined osteoporosis
characterizes clinical osteoporosis because such fractures rep-
resent evidence of compromised bone strength—indeed, prev-
alent vertebral fractures are more highly associated with low
bone strength by BCT than with low BMD by DXA [62–64].
Treating patients who have clinical signs of true osteopo-
rosis, and not just those with BMD-defined osteoporosis, is
effective. For example, drug trials to prevent new fractures
demonstrate efficacy in BMD-defined osteopenic patients
who have one or more existing vertebral fractures [113].
Also, alendronate has been shown to be more effective when
given to patients who have lower BMD T-scores [114]; pre-
sumably, those patients on average will have lower bone
strength because BMD T-scores and bone strength are corre-
lated (see Fig. 7). Collectively, these findings indicate that
osteoporosis medications are effective when given to patients
who have (true) osteoporosis, namely, those who show evi-
dence of compromised bone strength and increased risk of
fracture. Realizing that individual treatment decisions always
depend on patient-specific factors, older patients with fragile
bone strength but without BMD-defined osteoporosis should
be considered as candidates for treatment.
This clinical interpretation of BCT results is consistent
with, and can easily be incorporated into, the latest US-
based practice guidelines for assessing fracture risk and decid-
ing who to treat. Traditionally with DXA, patients are classi-
fied for fracture risk on the basis of the BMD-based classifi-
cations listed in Table 1: patients with osteoporosis by BMD
criteria are considered at high risk of fracture and thus are
candidates for treatment, patients with low bone mass are
considered at increased (or moderate) risk of fracture, and
patients with normal bone mass are not at increased risk of
fracture. That approach is the basis for the overall fracture risk
classification from the BCT test. Practice guidelines in the
USA also now include other metrics beyond BMD that clas-
sify who is at high risk of fracture [46, 79]. One important
metric is the FRAX-calculated 10-year absolute risk of hip or
other major osteoporotic fracture. That absolute risk in turn is
often used with cut-points to classify high-risk patients for
treatment: a 10-year hip fracture risk of 3% or more or a 10-
year risk of major osteoporotic fractures of 20% or more [46,
79]. The other important metric is a history of previous frac-
tures, particularly at the hip or spine. A new “very high-risk”
category has been defined as the patient presenting with
BMD-defined osteoporosis who also has multiple vertebral
fractures [79]. The classifications from BCT, shown in
Table 1, can be easily incorporated into these types of practice
guidelines by expanding the definition of high-risk and very
high-risk patients based on BMD criteria (T-score ≤ − 2.5 at
the hip or spine) to also consider the presence of fragile bone
strength. Further, while spinal coverage in abdominal CT
scans typically only extends over the lumbar region, sagittal
reconstructions from those scans can be useful nonetheless to
opportunistically identify any prevalent vertebral fracture in
that region [48, 49].
Another issue in using BCT clinically for patient care is
what to do about monitoring for a treatment response once a
BCT patient is placed on treatment. BCT, when used with a
dedicated CT scan, can be used to monitor. However, given
that opportunistic BCT has not yet been evaluated for moni-
toring treatment responses, we recommend that opportunistic
BCT patients can be monitored for a treatment response by
taking a baseline DXA once the patient is placed on treatment
and then a follow-up monitoring DXA as appropriate. For
repeated screening and fracture risk re-evaluation over
time—which is distinct from monitoring a treatment
response—any approved osteoporosis test, including opportu-
nistic or dedicated BCT, can be used at any time point, and
results interpreted appropriately.
BCT has some inherent limitations that should be recognized.
One important clinical caveat, which applies also to any BMD
measurement, is that BCT cannot detect any molecular level de-
fects in bone that might compromise bone strength independently
of the level of BMD. This is because clinical CTscans do not have
molecular level resolution, and the computational finite element
model used for BCT, which utilizes empirical relations from ca-
daver testing between BMD and the mechanical properties of
trabecular and cortical bone, implicitly assumes a typical relation
between CT-measured BMD and bone strength at the tissue level.
Thus, physicians should be aware of this feature when interpreting
results from a BCT test. For example, if a patient fractures without
trauma and has both highBMDand high bone strength fromBCT,
one can reasonably interpret that finding as indirect but good ev-
idence of compromised bone quality at the molecular level that
presumably weakens the bone [115].
Another limitation of both BCT and BMD measurements
for fracture risk assessment is that they only evaluate factors
directly related to identifying the presence of osteoporosis;
other factors related to fracture risk (e.g., fall risk) are not
currently included. As a new modality for osteoporosis test-
ing, and given its biomechanical and mechanistic nature, BCT
is likely to evolve. As summarized elsewhere [24, 26], further
improvements to BCT for measuring bone strength clinically
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might result from incorporating such characteristics as trabec-
ular orientation, enhanced cortical modeling, effects of aging
on bone tissue ductility, and multiple sideway fall loading
conditions—all topics of ongoing research [42, 97, 99, 100,
116]. In addition, beyond bone strength, other biomechanical
factors are also important in fracture etiology: for example,
fall risk, fall biomechanics, probabilistic loading, muscle
strength, overall skeletal geometry, and soft tissue-related en-
ergy absorption and force attenuation [41]. These and other
factors may eventually be integrated into BCT to more
completely and mechanistically assess overall fracture risk.
Finally, it is noteworthy also that the BCT results presented
here are limited to the specific implementation of BCT reviewed
here (VirtuOst). Due to BCT’s use to date primarily in research
settings, different implementations of BCT by different research
groups can provide different values of bone strength depending
on a number of technical factors. Such factors include specifics
of the image processing and calibration, the finite elementmodel-
ing choices (e.g., type of finite element, material property map-
ping), and perhaps most importantly, how the virtual stress test-
ing itself is configured, e.g., the bone orientation during the side-
ways fall or even the use of stance-like loading [26, 117]. Thus,
all BCT is not the same and different implementations of BCTby
different groups may produce different values of strength, requir-
ing, for example, different classification cut-points. That said,
one study reported different absolute measurements from two
different implementations of BCT but similar measurements of
treatment-induced percent changes [118], suggesting that BCT is
more robust across different implementations for assessing tem-
poral changes than absolute values. Related, the clinical term
“BCT” is intended only to apply to finite element analysis of
clinical-resolution CTscans and does not apply to finite element
analysis of other types of medical images. For example, finite
element analysis can be used with DXA [119, 120] and high-
resolution peripheral quantitative CT [121, 122] scans, but both
these applications are used primarily in research settings and are
not available for clinical diagnostic purposes.
In summary, long used as a research tool, at this juncture,
BCT is well established in terms of clinical efficacy and is now
available clinically as aMedicare-reimbursed osteoporosis test in
the USA. While it can be used with a dedicated CT, BCT is
particularly well suited for opportunistic use in the patient who
is already undergoing a hip- or spine-containing CT for other
purposes. The data presented here indicate that BCT used in this
way should provide a convenient, safe, and effective alternative
to DXA for those patients not already undergoingDXA andwho
would benefit from a comprehensive osteoporosis assessment.
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